Comparing Electromed (NYSE:ELMD) & Helius Medical Technologies (NASDAQ:HSDT)

Electromed (NYSE:ELMDGet Rating) and Helius Medical Technologies (NASDAQ:HSDTGet Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Electromed and Helius Medical Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Electromed 4.94% 5.77% 5.06%
Helius Medical Technologies -3,473.56% -198.39% -153.13%

Risk & Volatility

Electromed has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Electromed and Helius Medical Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Electromed 0 0 0 0 N/A
Helius Medical Technologies 0 1 0 0 2.00

Helius Medical Technologies has a consensus target price of $20.00, indicating a potential upside of 547.25%. Given Helius Medical Technologies’ higher possible upside, analysts plainly believe Helius Medical Technologies is more favorable than Electromed.

Insider & Institutional Ownership

39.3% of Electromed shares are owned by institutional investors. Comparatively, 26.3% of Helius Medical Technologies shares are owned by institutional investors. 26.7% of Electromed shares are owned by insiders. Comparatively, 17.4% of Helius Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Electromed and Helius Medical Technologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Electromed $35.76 million 3.02 $2.36 million $0.22 57.59
Helius Medical Technologies $520,000.00 22.56 -$18.13 million ($7.55) -0.41

Electromed has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Summary

Electromed beats Helius Medical Technologies on 9 of the 12 factors compared between the two stocks.

Electromed Company Profile (Get Rating)

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Helius Medical Technologies Company Profile (Get Rating)

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

Receive News & Ratings for Electromed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electromed and related companies with MarketBeat.com's FREE daily email newsletter.